Medical Condition News

RSS

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

Merrimack Pharmaceuticals, Inc. today announced Phase I clinical trial results for MM-302, the company's novel agent for the treatment of advanced HER2 positive (HER2+ or ErbB2+) breast cancer.

11 Dec 2012

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.

11 Dec 2012

UNM study to understand why and how DNA repair mechanisms go awry in cancer cells

DNA, like houses and cars, needs ongoing maintenance. Rays of ultraviolet sunlight, chemical pollutants and normal biochemical processes in the cell can damage it. Cells routinely repair this damage before making proteins or copying DNA for cell division. The repairs are remarkably accurate in normal cells but cancer cells make far more mistakes in fixing their DNA.

11 Dec 2012

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of new clinical data with the Company's targeted anticancer compound, IMGN901.

11 Dec 2012

Combination of diagnostic tests can predict conversion from MCI to Alzheimer's

A combination of diagnostic tests, including imaging and cerebrospinal fluid biomarkers can improve prediction of conversion from mild cognitive impairment (MCI) to Alzheimer's disease, according to a new study published online in the journal Radiology.

11 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

Isis, Biogen Idec partner to discover and develop antisense drugs against neuromuscular disorders

Biogen Idec and Isis Pharmaceuticals, Inc. today announced that they have entered into a global collaboration agreement under which the companies will discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders.

11 Dec 2012

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.

11 Dec 2012

Study finds silent reading difficulties in glaucoma patients

Better strategies are needed to help glaucoma patients cope with difficulty reading. According to a new scientific study published in Investigative Ophthalmology & Visual Science, adults with glaucoma read slower when reading silently for long periods of time and are more likely to have their reading speed decrease over time, possibly a result of reading fatigue.

11 Dec 2012

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced new data from its ongoing Phase 1, open-label, dose-escalation trial of IPI-145, the company's potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with advanced hematologic malignancies.

11 Dec 2012

Alpha arrestins may play a role in cell signaling that is crucial to new drug development

A newly found understanding of receptor signaling may have revealed a better way to design drugs. A study from Nationwide Children's Hospital suggests that a newly identified group of proteins, alpha arrestins, may play a role in cell signaling that is crucial to new drug development.

11 Dec 2012

Boston College professor to research into new drugs that can prevent onset of toxoplasmosis

The American Cancer Society has awarded a four-year, $720,000 grant to Boston College Associate Professor of Biology Marc-Jan Gubbels for research into potential new drugs that can prevent the onset of toxoplasmosis in cancer patients with weakened immune systems.

10 Dec 2012

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

New positive Phase II results from an interim analysis of the randomised Phase I/II study involving the company's investigational haematology/oncology compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy were presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, USA.

10 Dec 2012

Strong inverse association between caffeinated coffee intake and oral/pharyngeal cancer mortality

A new American Cancer Society study finds a strong inverse association between caffeinated coffee intake and oral/pharyngeal cancer mortality. The authors say people who drank more than four cups of caffeinated coffee per day were at about half the risk of death of these often fatal cancers compared to those who only occasionally or who never drank coffee.

10 Dec 2012

Patients with sickle cell disease rely more on emergency room

Patients with sickle cell disease rely more on the emergency room as they move from pediatric to adult health care, according to researchers at Washington University School of Medicine in St. Louis.

10 Dec 2012

Potential way to attack common stomach bacteria that cause ulcers

Experiments at the U.S. Department of Energy's (DOE) SLAC National Accelerator Laboratory have revealed a potential new way to attack common stomach bacteria that cause ulcers and significantly increase the odds of developing stomach cancer.

10 Dec 2012

Tips to prevent ‘holiday heart’ syndrome

The holiday season is supposed to be joyous, fun and happy. But it can also be stressful. The nation's emergency physicians want to remind all Americans to keep your stress in check.

10 Dec 2012

Pfizer joins WIN Consortium to improve personalized cancer care

Worldwide Innovative Network (WIN) in personalized cancer medicine consortium today proudly announced that Pfizer, Inc (NYSE:PFE) is the first pharmaceutical company to become a member of the consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of leading academic, industry, and patient advocacy organizations working to make personalized cancer care a reality for patients worldwide.

10 Dec 2012

Giving iron supplements to low birth weight infants reduces behavior problems later in life

In a study published today in Pediatrics, scientists at Umeå University in Sweden conclude that giving iron supplements to low birth weight infants reduces the risk of behavior problems like ADHD later in life.

10 Dec 2012

New study could help develop anti-inflammatory drugs with fewer side effects

10 Dec 2012

Medical Condition News

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

UNM study to understand why and how DNA repair mechanisms go awry in cancer cells

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

Combination of diagnostic tests can predict conversion from MCI to Alzheimer's

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Isis, Biogen Idec partner to discover and develop antisense drugs against neuromuscular disorders

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Study finds silent reading difficulties in glaucoma patients

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Alpha arrestins may play a role in cell signaling that is crucial to new drug development

Boston College professor to research into new drugs that can prevent onset of toxoplasmosis

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

Strong inverse association between caffeinated coffee intake and oral/pharyngeal cancer mortality

Patients with sickle cell disease rely more on emergency room

Potential way to attack common stomach bacteria that cause ulcers

Tips to prevent ‘holiday heart’ syndrome

Pfizer joins WIN Consortium to improve personalized cancer care

Giving iron supplements to low birth weight infants reduces behavior problems later in life

New study could help develop anti-inflammatory drugs with fewer side effects

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Latest News